NCT02824952View on ClinicalTrials.gov

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

PHASE2UnknownINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Lung Cancer, Non-small Cell

Interventions

DRUG

Tagrisso

taking orally everyday for 6 or 12 weeks.

Trial Locations (1)

Unknown

RECRUITING

Shaare Zedek Medical Center, Jerusalem

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Shaare Zedek Medical Center

OTHER